| Company Name: |
Twochem Co.Ltd. |
| Tel: |
021-58111628 15800915896 |
| Email: |
sales@twochem.com |
|
| | Lorlatinib acetate Basic information |
| | Lorlatinib acetate Chemical Properties |
| storage temp. | room temp | | solubility | DMSO: 2mg/mL, clear | | form | powder | | color | white to beige | | Optical Rotation | [α]/D -95 to -115°, c =0.5 in methanol | | InChIKey | IIXWYSCJSQVBQM-LLVKDONJSA-N | | SMILES | NC1=C(O[C@@H](C2=C3C=CC(F)=C2)C)C=C(C4=C(C#N)N(C)N=C4CN(C)C3=O)C=N1 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | Lorlatinib acetate Usage And Synthesis |
| Uses | PF-06463922 acetate has been used as an inhibitor of anaplastic lymphoma kinase (ALK) to analyze the expression of adrenomedullin using qPCR. | | Biological Activity | PF-06463922 is a potent, selective brain-penetrable inhibitor of both anaplastic lymphoma kinase (ALK) and c-ros Oncogene 1 (ROS1) with strong activity against all known ALK and ROS1 mutants identified in patients with crizotinib-resistant disease. PF-06463922 is in clinical trials for the treatment of non–small cell lung cancer (NSCLC). | | in vivo | In rats, Lorlatinib (PF-06463922) displays low plasma clearance, a moderate volume of distribution, a reasonable half-life, low propensity for p-glycoprotein 1-mediated efflux and a bioavailability of 100%[1]. In vivo, Lorlatinib shows cytoreductive antitumor efficacy in the NIH3T3 xenograft models expressing human CD74-ROS1 and Fig-ROS1 via inhibition in ROS1 phosphorylation and the downstream signaling molecules, as well as inhibition of the cell cycle protein Cyclin D1 in tumors. Lorlatinib also demonstrates marked antitumor activity in mice bearing tumor xenografts expressing EML4-ALK, EML4-ALK-L1196M, EML4-ALK-G1269A, EML4-ALK-G1202R or NPM-ALK[2]. |
| | Lorlatinib acetate Preparation Products And Raw materials |
|